These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 24939497

  • 21. Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome.
    Sedky AA, Magdy Y.
    Life Sci; 2020 Sep 01; 256():117960. PubMed ID: 32534033
    [Abstract] [Full Text] [Related]

  • 22. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
    Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG.
    J Pharmacol Exp Ther; 2013 Jan 01; 344(1):196-206. PubMed ID: 23090647
    [Abstract] [Full Text] [Related]

  • 23. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
    Fukudo S, Miwa H, Nakajima A, Haruma K, Kosako M, Nakagawa A, Akiho H, Yamaguchi Y, Johnston JM, Currie M, Kinoshita Y.
    Neurogastroenterol Motil; 2018 Dec 01; 30(12):e13444. PubMed ID: 30136447
    [Abstract] [Full Text] [Related]

  • 24. Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
    Fukudo S, Miwa H, Nakajima A, Kinoshita Y, Kosako M, Nakagawa A, Akiho H, Kuroishi K, Johnston JM, Currie M, Ohkusa T.
    Neurogastroenterol Motil; 2018 Dec 01; 30(12):e13442. PubMed ID: 30084233
    [Abstract] [Full Text] [Related]

  • 25. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
    Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ.
    Gastroenterology; 2010 Dec 01; 139(6):1877-1886.e2. PubMed ID: 20801122
    [Abstract] [Full Text] [Related]

  • 26. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
    Lee N, Wald A.
    Expert Opin Drug Metab Toxicol; 2011 May 01; 7(5):651-9. PubMed ID: 21446888
    [Abstract] [Full Text] [Related]

  • 27. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
    Vazquez Roque M, Camilleri M.
    Expert Rev Gastroenterol Hepatol; 2011 Jun 01; 5(3):301-10. PubMed ID: 21651347
    [Abstract] [Full Text] [Related]

  • 28. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Schoenfeld P, Lacy BE, Chey WD, Lembo AJ, Kurtz CB, Reasner DS, Bochenek W, Tripp K, Currie MG, Fox SM, Blakesley RE, OʼDea CR, Omniewski ND, Hall ML.
    Am J Gastroenterol; 2018 Jan 01; 113(1):105-114. PubMed ID: 29091082
    [Abstract] [Full Text] [Related]

  • 29. Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study.
    Pohl D, Fried M, Lawrance D, Beck E, Hammer HF.
    BMJ Open; 2019 Dec 30; 9(12):e025627. PubMed ID: 31892640
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation.
    Corsetti M, Tack J.
    United European Gastroenterol J; 2013 Feb 30; 1(1):7-20. PubMed ID: 24917937
    [Abstract] [Full Text] [Related]

  • 32. Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
    Sharma S, Sharma T, Dhingra R, Tomar P, Singh S, Malhotra M, Bhardwaj TR.
    Mini Rev Med Chem; 2013 Oct 30; 13(11):1685-90. PubMed ID: 24001336
    [Abstract] [Full Text] [Related]

  • 33. Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation.
    Farmer AD, Ruffle JK, Hobson AR.
    Neurogastroenterol Motil; 2019 Feb 30; 31(2):e13492. PubMed ID: 30353623
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Efficacy of linaclotide for patients with chronic constipation.
    Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Johnston JM.
    Gastroenterology; 2010 Mar 30; 138(3):886-95.e1. PubMed ID: 20045700
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis.
    Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC.
    Gastroenterology; 2018 Dec 30; 155(6):1753-1763. PubMed ID: 30144426
    [Abstract] [Full Text] [Related]

  • 37. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
    Thomas RH, Luthin DR.
    Pharmacotherapy; 2015 Jun 30; 35(6):613-30. PubMed ID: 26016701
    [Abstract] [Full Text] [Related]

  • 38. Linaclotide: a novel approach to the treatment of irritable bowel syndrome.
    Wensel TM, Luthin DR.
    Ann Pharmacother; 2011 Dec 30; 45(12):1535-43. PubMed ID: 22045908
    [Abstract] [Full Text] [Related]

  • 39. Linaclotide for constipation-predominant IBS.
    Drug Ther Bull; 2013 Nov 30; 51(11):129-32. PubMed ID: 24227771
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.